メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
Keio University ホーム
ヘルプ＆FAQ
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
泌尿器科学
医学部
医学部臨床教室
概要
フィンガープリント
ネットワーク
プロファイル
(11)
研究成果
(799)
フィンガープリント
泌尿器科学が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Transitional Cell Carcinoma
100%
Clear Cell Renal Cell Carcinoma
96%
Neoplasm
83%
Prostate Cancer
75%
Recurrent Disease
51%
Nephroureterectomy
47%
Prostatectomy
33%
Malignant Neoplasm
33%
Bladder Cancer
32%
Prostate Specific Antigen
29%
Kidney Metastasis
28%
Castration Resistant Prostate Cancer
28%
Overall Survival
27%
Non Muscle Invasive Bladder Cancer
25%
Survival Rate
22%
Adrenalectomy
21%
Cystectomy
21%
Disease
20%
Multivariate Analysis
20%
Metastatic Carcinoma
20%
Upper Urinary Tract
19%
Computer Assisted Tomography
19%
Magnetic Resonance Imaging
19%
Sunitinib
17%
Cancer Cell
17%
Nephrectomy
16%
Progression Free Survival
16%
Tumor Recurrence
16%
Bacilli
16%
Cisplatin
16%
Biopsy
15%
Urothelial Cancer
15%
Cancer Specific Survival
15%
Bladder Tumor
15%
Recurrence Free Survival
15%
Nivolumab
15%
Biological Marker
14%
Prognostic Factor
14%
Biochemical Recurrence
14%
Pembrolizumab
14%
Androgen Deprivation Therapy
13%
Subgroup Analysis
13%
Hazard Ratio
13%
Brachytherapy
13%
Bladder
13%
Adverse Event
11%
Operation Duration
11%
Kidney Function
11%
Cancer Staging
10%
Partial Nephrectomy
10%
Gleason Score
10%
Cabazitaxel
9%
Laparoendoscopic Single Site Surgery
9%
Hormone Therapy
9%
Angiomyolipoma
9%
Radiation Therapy
9%
Lymphovascular Invasion
9%
Radical Nephrectomy
9%
Retrospective Study
9%
Targeted Therapy
9%
Transurethral Resection
9%
Body Mass Index
9%
Ureter
8%
Tyrosine-Kinase Inhibitor
8%
Pelvis
8%
Neoadjuvant Chemotherapy
8%
Papillary Renal Cell Carcinomas
8%
Cancer
8%
Axitinib
8%
Immunohistochemistry
8%
Echography
8%
Lymph Node
8%
Microvessel
7%
Hydronephrosis
7%
Carcinoma in Situ
7%
Neutrophil
7%
Pneumoperitoneum
7%
Lymphocyte
7%
Urine Cytology
7%
Visceral Fat
7%
Proportional Hazards Model
7%
Clinical Trial
7%
Kidney Tumour
7%
Adjuvant Chemotherapy
6%
Computed Tomography Urography
6%
Urinary Tract
6%
Sodium Fluoride
6%
Bleeding
6%
Diagnosis
6%
Lung Metastasis
6%
Bone Metastasis
6%
Urologist
6%
Retroperitoneal Lymph Node Dissection
6%
Lenvatinib
6%
Urinary System
6%
Immune Checkpoint Inhibitor
6%
Programmed Death 1 Ligand 1
5%
Breast Cancer
5%
Kidney Cancer
5%
Arm
5%
Pharmacology, Toxicology and Pharmaceutical Science
Renal Cell Carcinoma
81%
Transitional Cell Carcinoma
58%
Neoplasm
57%
Prostate Cancer
54%
Castration Resistant Prostate Cancer
44%
Malignant Neoplasm
38%
Kidney Metastasis
36%
Overall Survival
33%
Recurrent Disease
32%
Bladder Cancer
30%
Non Muscle Invasive Bladder Cancer
30%
Chemotherapy
26%
Progression Free Survival
24%
Prostate Specific Antigen
21%
Cisplatin
20%
Survival Rate
20%
Axitinib
20%
Androgen
19%
Disease
19%
Sunitinib
19%
Tumor Recurrence
18%
Adverse Event
16%
Biological Marker
15%
Cabazitaxel
14%
Docetaxel
14%
Bacilli
14%
Nivolumab
14%
Sorafenib
13%
Retrospective Study
12%
Mouse
12%
Avelumab
11%
Biochemical Recurrence
11%
Dehydroxymethylepoxyquinomicin
11%
Bladder Tumor
11%
Nuclear Factor
10%
Alternative Complement Pathway C3 C5 Convertase
10%
C Reactive Protein
10%
Recurrence Free Survival
10%
Angiotensin II
9%
Pembrolizumab
8%
Vasculotropin
8%
Kidney Cancer
8%
Cytokine
7%
Tumor Growth
7%
Cancer Specific Survival
7%
Interleukin 2
7%
Gemcitabine
7%
Drug Resistance
7%
Receptor
6%
Protein Tyrosine Kinase Inhibitor
6%
Gleason Score
6%
Symptom
6%
Dutasteride
6%
Clinical Trial
5%
Candesartan
5%
Renin
5%
Bone Metastasis
5%
Hemodialysis
5%
Cancer Staging
5%
Fluorouracil
5%
Keyphrases
Upper Tract Urothelial Carcinoma
30%
Advanced Renal Cell Carcinoma
23%
Renal Cell Carcinoma
21%
Metastatic Renal Cell Carcinoma (mRCC)
20%
Japanese Patients
15%
Nephroureterectomy
15%
Castration-resistant Prostate Cancer
15%
Clinical Outcomes
13%
Japan
13%
Non-muscle Invasive Bladder Cancer (NMIBC)
13%
Prostate Cancer Patients
13%
Radical Prostatectomy
12%
Sunitinib
11%
Axitinib
10%
Overall Survival
10%
Japanese Urological Association
10%
Cancer-specific Survival
10%
Tumor
9%
Prostate Cancer
9%
Cancer Patients
9%
Avelumab
8%
Confidence Interval
8%
Hazard Ratio
8%
Bladder Cancer
8%
Biochemical Recurrence
8%
Androgen Deprivation Therapy
7%
Sorafenib
7%
Vasohibin-1
7%
Progression-free Survival
6%
Programmed Death-ligand 1 (PD-L1)
6%
Prostate-specific Antigen
6%
Prognostic Significance
6%
Nivolumab
6%
Muscle-invasive Bladder Cancer
6%
Radical Cystectomy
6%
Multi-institutional
6%
Renal Impairment
5%
Pembrolizumab
5%
Targeted Therapy
5%
Survival Rate
5%
Multivariate Analysis
5%
Recurrence-free Survival
5%
Clinical Practice Guidelines
5%
Prognostic Value
5%